INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
07/24/2024
Back to search
Official data from USPTO
ILLIMIS THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/24/2024
Classification
Registered
Trademark type
Combined
Nice classes
5, 42
Filing date
03/17/2022
Registration date
07/04/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/04/2023
Last transaction
10/14/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
KR
Examiner
THOMAS, JULIE
Law office
L70
Current location
TMEG LAW OFFICE 107
Mark description
The mark consists of the wording "ILLIMIS THERAPEUTICS", in stylized font, with the first letter "I", the letters "IMIS" and "THERAPEUTICS" in blue, the first letter "L" in light blue and the second letter "L" in yellow.
Holders and representatives
Holders
Illimis Therapeutics, Inc.
Representatives
Jong Park The PL Law Group, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growthshemolytic diseases and disordersamyloidosismetabolic diseases and disorderslupusinflammation and autoimmune diseases and disorders
Class 42
Pharmaceutical product development; pharmaceutical research and development in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady/disease and dysfunction; scientific research in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; * pharmaceutical research and development in the field of age-related diseasesdisorders and degenerative diseases; pharmaceutical research and development in the field of chronic maladydisease and dysfunction; scientific research for medical purpose in the field of gene therapy; biotechnology research; scientific research for medical purpose in the field of cancer disease; medical research of autoimmune disease; * pharmaceutical research and development in the field of inflammatory disease; pharmaceutical research and development in the field of eye disease; pharmaceutical research and development in the field of amyloidosis; * pharmaceutical * consultancy and information services relating to pharmaceutical quality control * ; providing information about pharmaceuticals research relating to pharmaceutical quality control *
Publications
History of USPTO decisions and trademark events.
32 publications found
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/18/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/06/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/16/2024
FIMP
FINAL DISPOSITION PROCESSED
01/16/2024
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
11/21/2023
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
10/16/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/14/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
10/14/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/04/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/21/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/18/2023
PUBO
PUBLISHED FOR OPPOSITION
04/18/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/29/2023
RFNT
REFUSAL PROCESSED BY IB
03/21/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/27/2023
RFRR
REFUSAL PROCESSED BY MPU
02/27/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/01/2023
CNRT
NON-FINAL ACTION WRITTEN
12/31/2022
DOCK
ASSIGNED TO EXAMINER
12/29/2022
MAFR
APPLICATION FILING RECEIPT MAILED
06/14/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/09/2022
Continuous trademark protection
Get notified about every new filing that threatens ILLIMIS THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.